Siltuximab - EUSA Pharma/Janssen Biotech
Alternative Names: Anti-interleukin-6 monoclonal antibody - Centocor; cCLB8; Chimeric anti-interleukin-6 monoclonal antibody - Centocor; CNTO-328; SylvantLatest Information Update: 06 Mar 2024
At a glance
- Originator Janssen Biotech
- Developer BeiGene; Centocor; EUSA Pharma; Janssen Biotech; Memorial Sloan-Kettering Cancer Center; Papa Giovanni XXIII Hospital
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Giant lymph node hyperplasia
- Phase III SARS-CoV-2 acute respiratory disease
- Phase II Multiple myeloma
- No development reported Paraproteinaemia; Smoldering multiple myeloma
- Discontinued Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Renal cell carcinoma
Most Recent Events
- 01 Jan 2024 China includes Siltuximab into the latest National Reimbursement Drug List 2024 (NRDL)
- 28 Apr 2023 No recent reports of development identified for clinical-Phase-Unknown development in SARS-COV-2 acute respiratory disease in Italy (IV)
- 11 Dec 2021 Efficacy data from the phase II in multicentric castleman disease (iMCD) presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-2021)